MY195528A - 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar - Google Patents

5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar

Info

Publication number
MY195528A
MY195528A MYPI2018001546A MYPI2018001546A MY195528A MY 195528 A MY195528 A MY 195528A MY PI2018001546 A MYPI2018001546 A MY PI2018001546A MY PI2018001546 A MYPI2018001546 A MY PI2018001546A MY 195528 A MY195528 A MY 195528A
Authority
MY
Malaysia
Prior art keywords
taar
pyrazole
agonist
ethyl
methyl
Prior art date
Application number
MYPI2018001546A
Other languages
English (en)
Inventor
Guido Galley
Marius Hoener
Roger Norcross
Philippe Pflieger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY195528A publication Critical patent/MY195528A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI2018001546A 2016-03-17 2017-03-14 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar MY195528A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16160790 2016-03-17
PCT/EP2017/055885 WO2017157873A1 (en) 2016-03-17 2017-03-14 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Publications (1)

Publication Number Publication Date
MY195528A true MY195528A (en) 2023-01-30

Family

ID=55542549

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018001546A MY195528A (en) 2016-03-17 2017-03-14 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar

Country Status (33)

Country Link
US (2) US10508107B2 (cg-RX-API-DMAC7.html)
EP (2) EP3757102A1 (cg-RX-API-DMAC7.html)
JP (1) JP6814814B2 (cg-RX-API-DMAC7.html)
KR (2) KR102537050B1 (cg-RX-API-DMAC7.html)
CN (1) CN108713019B (cg-RX-API-DMAC7.html)
AR (1) AR107878A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017234042B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018015389B1 (cg-RX-API-DMAC7.html)
CA (1) CA3013696C (cg-RX-API-DMAC7.html)
CL (1) CL2018002583A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018007515A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180443A (cg-RX-API-DMAC7.html)
DK (1) DK3430010T3 (cg-RX-API-DMAC7.html)
ES (1) ES2819830T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201405T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050986T2 (cg-RX-API-DMAC7.html)
IL (1) IL260473B (cg-RX-API-DMAC7.html)
LT (1) LT3430010T (cg-RX-API-DMAC7.html)
MA (2) MA53755A (cg-RX-API-DMAC7.html)
MX (1) MX377836B (cg-RX-API-DMAC7.html)
MY (1) MY195528A (cg-RX-API-DMAC7.html)
PE (1) PE20181446A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018501588A1 (cg-RX-API-DMAC7.html)
PL (1) PL3430010T3 (cg-RX-API-DMAC7.html)
PT (1) PT3430010T (cg-RX-API-DMAC7.html)
RS (1) RS60825B1 (cg-RX-API-DMAC7.html)
RU (1) RU2731095C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201807516UA (cg-RX-API-DMAC7.html)
SI (1) SI3430010T1 (cg-RX-API-DMAC7.html)
TW (1) TWI634117B (cg-RX-API-DMAC7.html)
UA (1) UA122881C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017157873A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804943B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022000181A2 (pt) 2019-07-11 2022-02-22 Hoffmann La Roche Processo para a preparação de derivados de pirazol substituídos
JP2023517729A (ja) 2020-03-19 2023-04-26 エフ． ホフマン－ラ ロシュ アーゲー Ｔａａｒ１アゴニストの塩形態および結晶形態
WO2023079128A1 (en) 2021-11-08 2023-05-11 F. Hoffmann-La Roche Ag Catalytic hydrogenation of aromatic nitro compounds
CN114288304A (zh) * 2021-12-31 2022-04-08 江苏海洋大学 一种抗精神分裂症组合物及其应用
AR129909A1 (es) 2022-07-15 2024-10-09 Hoffmann La Roche Cetorreductasa mutante con mayor actividad de cetorreductasa así como métodos y usos de esta
CN119654138A (zh) 2022-08-12 2025-03-18 豪夫迈·罗氏有限公司 包含5-乙基-4-甲基-n-[4-[(2s)吗啉-2-基]苯基]-1h-吡唑-3-甲酰胺的药物组合物
EP4568654A1 (en) * 2022-08-12 2025-06-18 F. Hoffmann-La Roche AG Use of co-processed excipients in continuous manufacturing of solid dosage forms
TW202440563A (zh) * 2022-11-28 2024-10-16 美商住友製藥美國公司 2-苯基嗎啉與2-苯基(硫代)嗎啉化合物及其用途
WO2024222860A1 (zh) * 2023-04-28 2024-10-31 江苏豪森药业集团有限公司 一种吗啉杂环类化合物的盐及其制备方法和应用
WO2024258900A2 (en) * 2023-06-13 2024-12-19 University Of Georgia Research Foundation, Inc. Plasmodium falciparum blood stage inhibitors

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731471A (en) 1956-01-17 Nxg hi
FR6551E (fr) 1905-07-27 1906-12-17 Carlo Chiesa Séchoir à tambour rotatif, démontable et transportable, et fonctionnant à ciel ouvert, pour cocons, céréales, etc.
US2161938A (en) 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
DE842065C (de) 1950-07-30 1952-06-23 Bayer Ag Verfahren zur Herstellung stickstoffhaltiger heterocyclischer Verbindungen
US2778836A (en) 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744909A (en) 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2744910A (en) 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2919274A (en) 1957-09-17 1959-12-29 Sahyun Melville Amidines
GB877306A (en) 1958-04-21 1961-09-13 Pfizer & Co C Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines
DE1083803B (de) 1958-05-30 1960-06-23 Bayer Ag Verfahren zur Herstellung von Derivaten der Anthranil-N-carbonsaeure
DE1121054B (de) 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
FR1355049A (fr) 1962-04-12 1964-03-13 Merck Ag E Agent pour le traitement préalable de la peau en vue du rasage
DE1150180B (de) 1962-04-12 1963-06-12 Merck Ag E Mittel zur Vorbehandlung der Haut fuer die Rasur
US3459763A (en) 1966-01-25 1969-08-05 Geigy Chem Corp Certain amino imidazole derivatives
ES323985A1 (es) 1966-02-26 1966-12-16 Blade Pique Juan Procedimiento para la obtenciën de derivados del imidazol
GB1180794A (en) 1966-08-05 1970-02-11 Boehringer Sohn Ingelheim Novel Arylhydrazino-Imidazolines and Preparation Thereof
US3377247A (en) 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
US3577415A (en) 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-substituted phenoxypyrrolidines
US3577428A (en) 1969-04-14 1971-05-04 Colgate Palmolive Co 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines
BE754935A (fr) 1969-08-13 1971-02-17 Hoechst Ag 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation
US3622579A (en) 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3818094A (en) 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3660423A (en) 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
DE2123243A1 (de) 1971-05-11 1972-11-16 Hupfauf, Lorenz, 8510 Fürth Verfahren und Vorrichtung zum Schneiden oder Falten von Bahnen aus Papier-, Zellstoff od. dgl
DE2123246C2 (de) 1971-05-11 1982-11-25 Basf Ag, 6700 Ludwigshafen 6-[p-(β-Phenyläthylaminoacetylamino)-phenyl]-4,5-dihydropyridazon-(3)
DE2253555A1 (de) 1972-11-02 1974-05-09 Hoechst Ag Oxazolo-pyrimidine und verfahren zu ihrer herstellung
US3981814A (en) 1973-09-18 1976-09-21 Givaudan Corporation Bacteriostatic substituted benzanilide compositions and methods for their use
CH609558A5 (en) 1973-09-18 1979-03-15 Givaudan & Cie Sa Antibacterial composition
US4125620A (en) 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
DE2446758C3 (de) 1974-10-01 1979-01-04 C.H. Boehringer Sohn, 6507 Ingelheim 2-(2-Fluor-6-trifluormethylphenylimino)-imidazolidin, dessen Säureadditionssalze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung der Hypertonie
US3992403A (en) 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4323570A (en) 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE2849537C2 (de) 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4311840A (en) 1980-11-13 1982-01-19 E. R. Squibb & Sons, Inc. 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones
US4735959A (en) 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
DE3133887A1 (de) 1981-08-27 1983-03-10 Bayer Ag, 5090 Leverkusen 2-arylhydrazino-2-imidazoline, deren acylderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von endo- und ektoparasiten
ES8405770A1 (es) 1982-01-27 1984-06-16 Pfizer Un procedimiento para la preparacion de una composicion ectoparasiticida, especialmente acaricida, o antihelmintica.
DE3302021A1 (de) 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
US4540705A (en) 1983-03-14 1985-09-10 Sterling Drug Inc. Antidepressant imidazolines and related compounds
DE3583900D1 (de) 1984-06-06 1991-10-02 Abbott Lab Adrenergische verbindungen.
DK302185A (da) 1984-07-05 1986-01-06 Rolland Sa A 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling
JPS61233678A (ja) 1985-04-09 1986-10-17 Maruko Seiyaku Kk ベンジルピペラジン誘導体
US4665095A (en) 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB2215206B (en) 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
DE3830054A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
FR2645860B1 (fr) 1989-04-14 1991-07-26 Sarget Lab Nouvelles aryloxymethyl-5 amino-2 oxazolines, syntheses et applications therapeutiques
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DE69127002T2 (de) 1990-01-31 1997-11-20 Fuji Photo Film Co Ltd Farbphotographisches Silberhalogenidmaterial
ES2245782T3 (es) 1993-10-13 2006-01-16 H. Joseph Horacek Formula de clonidina de liberacion prolongada.
EP0661266A1 (en) 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
DE19514579A1 (de) 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5610174A (en) 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
PT748800E (pt) 1995-06-09 2001-10-30 Hoffmann La Roche Derivados de pirimidinadiona pirimidinatriona triazinadiona como antagonistas do receptor alfa-1-adrenergico
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
EP0922029B1 (en) 1996-08-15 2005-06-08 Schering Corporation Ether muscarinic antagonists
US5969137A (en) 1996-09-19 1999-10-19 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
GB9625145D0 (en) 1996-12-03 1997-01-22 Smithkline Beecham Plc Novel compounds
ZA981029B (en) 1997-02-11 1999-08-10 Lilly Co Eli Pharmaceutical agents.
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
US6184242B1 (en) 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
CA2312334A1 (en) 1997-12-04 1999-06-10 Allergan Sales, Inc. Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
WO1999032112A1 (en) 1997-12-19 1999-07-01 Eli Lilly And Company Method for treating diabetes
WO1999054309A1 (en) 1998-04-23 1999-10-28 Takeda Chemical Industries, Ltd. Naphthalene derivatives, their production and use
DE19826517B4 (de) 1998-06-15 2006-03-23 Baxter Healthcare S.A. Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
ES2150378B1 (es) 1998-08-07 2001-07-01 Esteve Labor Dr Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
CA2246027A1 (en) 1998-08-27 2000-02-27 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
CN1213658C (zh) 1998-11-04 2005-08-10 明治制果株式会社 吡啶甲酰胺衍生物、含有其作为有效成分的有害生物防除剂
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CN1206219C (zh) 1998-12-18 2005-06-15 布里斯托尔-迈尔斯斯奎布药品公司 作为趋化因子受体活性调节剂的n－脲基烷基－哌啶化合物
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
DK1163212T3 (da) 1999-03-17 2005-11-14 Astrazeneca Ab Amidderivater
CA2373510A1 (en) 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP2001151742A (ja) 1999-11-26 2001-06-05 Mitsui Chemicals Inc アニリド誘導体及びそれを含有する抗不整脈剤
FR2802533B1 (fr) 1999-12-17 2002-02-15 Sanofi Synthelabo Phenoxypropanolamines, leur preparation et leur application en therapeutique
JP2001302643A (ja) 2000-04-21 2001-10-31 Suntory Ltd 環状アミジン化合物
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
WO2002022801A2 (en) 2000-09-12 2002-03-21 Oregon Health & Science University Mammalian receptor genes and uses
AU2180802A (en) 2000-11-14 2002-05-27 Hoffmann La Roche Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
WO2002053544A1 (en) 2000-12-29 2002-07-11 Darwin Discovery Ltd. Pharmaceutical uses and synthesis of nicotinanilide-n-oxides
EP1360173A2 (en) 2001-01-25 2003-11-12 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
CN100343255C (zh) 2002-04-23 2007-10-17 盐野义制药株式会社 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
TW200306783A (en) 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
AU2003243318A1 (en) 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
UA77536C2 (en) 2002-07-03 2006-12-15 Lundbeck & Co As H Secondary aminoaniline piperidines as mch1 antagonists and their use
KR100492252B1 (ko) 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
CA2510471A1 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
US6933311B2 (en) 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2415760A3 (en) 2003-02-20 2012-02-22 Encysive Pharmaceuticals, Inc. CCR-9 antagonists
JP2006523692A (ja) 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
WO2005014554A1 (en) 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
BRPI0415167A (pt) 2003-10-07 2006-11-28 Renovis Inc composto de amina como ligandos de canal de ìon e usos dos mesmos
US7432281B2 (en) 2003-10-07 2008-10-07 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
BRPI0415833A (pt) 2003-10-23 2007-01-02 Hoffmann La Roche derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos
KR101122708B1 (ko) 2003-12-26 2012-03-26 마사토시 하기와라 Ｓｒ 단백질 인산화 제어 방법, 및 유효성분으로서 ｓｒ 단백질 활성 제어제를 함유하는 항바이러스제
US8404747B2 (en) 2004-03-05 2013-03-26 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
WO2005105763A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
SI1761520T1 (sl) 2004-06-23 2008-10-31 Lilly Co Eli Inhibitorji kinaze
EP1764360A4 (en) 2004-07-02 2010-08-11 Sankyo Co UREA DERIVATIVE
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2008509982A (ja) 2004-08-16 2008-04-03 プロシディオン・リミテッド アリール尿素誘導体
WO2006051851A1 (ja) 2004-11-10 2006-05-18 Wakamoto Pharmaceutical Co., Ltd. ２，３，４，５－テトラヒドロ－１ｈ－１，５－ベンゾジアゼピン誘導体、及び、医薬組成物
US20060111392A1 (en) 2004-11-23 2006-05-25 Wood Michael R Substituted biaryl-carboxylate derivatives
WO2006070878A1 (ja) 2004-12-28 2006-07-06 Astellas Pharma Inc. カルボン酸誘導体またはその塩
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
RU2007131101A (ru) 2005-01-21 2009-02-27 Астекс Терапьютикс Лимитед (Gb) Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований
MX2007008810A (es) 2005-01-21 2007-11-21 Astex Therapeutics Ltd Compuestos farmaceuticos.
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006107923A1 (en) 2005-04-05 2006-10-12 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
BRPI0610195A2 (pt) 2005-05-03 2010-06-01 Bayer Cropscience Ag derivados inseticidas de aminoalquil heterociclila e heteroarila substituìdas
EP1900087A2 (en) 2005-07-06 2008-03-19 Cambridge Semiconductor Limited Switch mode power supply control systems
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
WO2007017728A2 (en) 2005-08-05 2007-02-15 Orchid Research Laboratories Limited Novel heterocyclic compounds
BRPI0615307A2 (pt) 2005-08-25 2009-08-04 Schering Corp agonistas de adrenorreceptor alfa2c
DK1940786T3 (da) 2005-09-16 2010-11-08 Arrow Therapeutics Ltd Biphenylderivater og deres anvendelse ved behandling af hepatitis C
US7754773B2 (en) 2005-10-06 2010-07-13 University Of Massachusetts Composition and synthesis of new reagents for inhibition of HIV replication
US20070197529A1 (en) 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
JP2007191471A (ja) 2005-12-21 2007-08-02 Sankyo Co Ltd ウレア誘導体を含有する医薬
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
ES2338716T3 (es) 2006-01-27 2010-05-11 F.Hoffmann-La Roche Ag Uso de derivados de 4-imidazol para trastornos del snc.
US8163746B2 (en) 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
PE20080345A1 (es) 2006-06-28 2008-05-29 Glaxo Group Ltd Derivados de piperazina como agonistas del receptor de gpr38
ATE546437T1 (de) 2006-10-19 2012-03-15 Hoffmann La Roche Aminomethyl-4-imidazole
CN101568527A (zh) 2006-10-31 2009-10-28 先灵公司 作为蛋白激酶抑制剂的2-氨基噻唑-4-羧酰胺
CA2668210C (en) 2006-10-31 2013-03-12 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
WO2008058033A2 (en) 2006-11-03 2008-05-15 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis
CN101568520A (zh) 2006-12-26 2009-10-28 参天制药株式会社 具有脲结构的新型n-(2-氨基苯基)苯甲酰胺衍生物
NZ578260A (en) 2007-02-02 2012-02-24 Hoffmann La Roche Novel 2-aminooxazolines as taar1 ligands for cns disorders
ES2525229T3 (es) 2007-02-15 2014-12-19 F. Hoffmann-La Roche Ag 2-aminooxazolinas como ligandos de TAAR1
AU2008253118B2 (en) 2007-05-22 2013-11-21 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
CN101678019B (zh) 2007-06-08 2016-03-30 詹森药业有限公司 哌啶/哌嗪衍生物
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
EP2182935A1 (en) 2007-08-02 2010-05-12 F. Hoffmann-Roche AG The use of benzamide derivatives for the treatment of cns disorders
BRPI0814758A2 (pt) 2007-08-03 2015-03-03 Hoffmann La Roche Piridinacarboxamida e derivados de benzamida como ligantes taar1
JP2009094891A (ja) 2007-10-10 2009-04-30 Toshiba Corp 半導体集積回路装置及びパターン検出方法
US8093428B2 (en) 2007-10-26 2012-01-10 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
CN101434570B (zh) 2007-11-16 2011-02-02 上海医药工业研究院 吡咯烷衍生物及其制备方法和应用
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010010014A1 (en) 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
JP5605844B2 (ja) 2008-10-17 2014-10-15 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体
ES2432070T3 (es) 2009-02-24 2013-11-29 Respiratorius Ab Diazaheteroarilos broncodilatadores novedosos
EP2411526A4 (en) 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF GANGLIOSID BIOSYNTHESIS
JP5381257B2 (ja) 2009-04-09 2014-01-08 ユニマテック株式会社 含フッ素ボロン酸エステル化合物の製造方法
WO2010118347A2 (en) 2009-04-10 2010-10-14 Zacharon Pharmaceuticals, Inc. O-linked glycan biosynthesis modulators
US20100311798A1 (en) 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011079091A1 (en) 2009-12-22 2011-06-30 Celgene Corporation (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
MX350761B (es) 2009-12-22 2017-09-18 Vertex Pharma Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
DE102011112317B3 (de) 2011-09-02 2013-02-28 Mühlbauer Ag Wendevorrichtung für Identifikationsgegenstände
EP2802324A4 (en) 2012-01-09 2015-07-15 X Rx Inc BENZHYDROL-PYRAZOLE DERIVATIVES WITH KINASE-INHIBITORY EFFECT AND USES THEREOF
UA113776C2 (xx) * 2012-09-14 2017-03-10 Похідні піразолкарбоксаміду як модулятори рецепторів слідових амінів (taar) для застосування при лікуванні різних розладів, таких як депресія, діабет та хвороба паркінсона
KR101676208B1 (ko) * 2012-09-17 2016-11-14 에프. 호프만-라 로슈 아게 트라이아졸 카복스아미드 유도체
CN104109165A (zh) 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
WO2015181061A1 (en) 2014-05-28 2015-12-03 F. Hoffmann-La Roche Ag 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as taar1 modulators
WO2016015333A1 (en) * 2014-08-01 2016-02-04 F.Hoffmann-La Roche Ag 2-oxa-5-azabicyclo [2.2.1] heptan-3-yl derivatives
RU2017107521A (ru) 2014-08-27 2018-10-01 Ф. Хоффманн-Ля Рош Аг Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar
EP4183798A1 (en) 2017-01-09 2023-05-24 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy

Also Published As

Publication number Publication date
TWI634117B (zh) 2018-09-01
PE20181446A1 (es) 2018-09-12
DK3430010T3 (da) 2020-09-21
EP3430010A1 (en) 2019-01-23
BR112018015389A2 (pt) 2018-12-18
MA43706B1 (fr) 2020-09-30
RU2018134262A (ru) 2020-04-17
EP3757102A1 (en) 2020-12-30
RU2018134262A3 (cg-RX-API-DMAC7.html) 2020-04-17
CR20180443A (es) 2018-11-21
WO2017157873A1 (en) 2017-09-21
CA3013696A1 (en) 2017-09-21
HUE050986T2 (hu) 2021-01-28
RS60825B1 (sr) 2020-10-30
UA122881C2 (uk) 2021-01-13
SG11201807516UA (en) 2018-09-27
JP2019512469A (ja) 2019-05-16
HRP20201405T1 (hr) 2020-11-27
SI3430010T1 (sl) 2020-10-30
BR112018015389B1 (pt) 2023-12-19
CO2018007515A2 (es) 2018-07-31
EP3430010B1 (en) 2020-07-15
CL2018002583A1 (es) 2018-12-28
PH12018501588A1 (en) 2019-04-08
AU2017234042B2 (en) 2020-11-19
PT3430010T (pt) 2020-09-10
US20190010148A1 (en) 2019-01-10
MX377836B (es) 2025-03-11
LT3430010T (lt) 2020-10-12
AU2017234042A1 (en) 2018-07-26
JP6814814B2 (ja) 2021-01-20
CA3013696C (en) 2024-04-16
ES2819830T3 (es) 2021-04-19
AR107878A1 (es) 2018-06-13
KR20180117640A (ko) 2018-10-29
NZ744194A (en) 2024-09-27
PL3430010T3 (pl) 2020-11-16
SG10201913878YA (en) 2020-03-30
TW201736365A (zh) 2017-10-16
US11312711B2 (en) 2022-04-26
CN108713019A (zh) 2018-10-26
CN108713019B (zh) 2021-06-15
IL260473B (en) 2020-11-30
RU2731095C2 (ru) 2020-08-28
US20210122743A1 (en) 2021-04-29
MX2018010622A (es) 2019-01-17
ZA201804943B (en) 2023-02-22
US10508107B2 (en) 2019-12-17
KR102415797B1 (ko) 2022-07-04
KR102537050B1 (ko) 2023-05-26
KR20220093400A (ko) 2022-07-05
MA53755A (fr) 2021-08-04

Similar Documents

Publication Publication Date Title
PH12018501588A1 (en) 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
PH12018500777A1 (en) Farnesoid x receptor modulators
MX391812B (es) Agonista fxr derivado de esteroides.
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
TN2016000210A1 (en) Urea derivative or pharmacologically acceptable salt thereof.
PH12017501297B1 (en) Cyclic amine derivative and pharmaceutical use thereof
ZA202002762B (en) Benzimidazole derivatives and their uses
PH12018501434A1 (en) Cyclic amine derivative and medical use thereof
WO2015100092A3 (en) 7-beta analogs of orvinols
CY1125352T1 (el) Κρυσταλλικες ενωσεις
MX2016014939A (es) Derivados de carboxamida.
MX2016005030A (es) Benzazepinas fusionadas para el tratamiento de la tartamudez.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
NZ707946A (en) Hydantoin derivative
EA201891431A1 (ru) Способы получения замещенного 5,6-дигидро-6- фенилбензо[f]изохинолин-2-амина
UA107702C2 (xx) Похідні бензаміду
NZ735249A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease
EA201690908A1 (ru) Пиразолопиримидиновые соединения
AU2018279669A8 (en) Carboxylic acid derivative as at AT2R receptor antagonist
MY170491A (en) Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters
MX2017011129A (es) Derivado de amina ciclica y uso farmaceutico del mismo.
EA201692485A1 (ru) Новая полиморфная форма n-[2-(6-фтор-1h-индол-3-ил)этил]-3-(2,2,3,3-тетрафторпропокси)бензиламина гидрохлорида для лечения болезни альцгеймера
MX2017011120A (es) Derivado de amina ciclica y uso farmaceutico del mismo.
PH12020551049A1 (en) Cyclic amine derivative and medical use thereof
UA121403U (uk) Спосіб підвищення продуктивності свиней та поліпшення якості свинини за використання кормової добавки "бетаїн"